Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab.

Related Articles Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Aliment Pharmacol Ther. 2018 Nov 08;: Authors: Feagan BG, Lam G, Ma C, Lichtenstein GR Abstract BACKGROUND: Biosimilar versions of widely prescribed drugs, including the tumour-necrosis factor antagonist infliximab, are becoming increasingly available. As biosimilars are not identical copies of reference products, evidence may be required to demonstrate that switching between a reference biologic and biosimilars is safe and efficacious. To establish interchangeability, US Food and Drug Administration guidance states that studies must demonstrate that…

Read More

Trick or TREAT? More Safety Data of Infliximab During Pregnancy.

Related Articles Trick or TREAT? More Safety Data of Infliximab During Pregnancy. Am J Gastroenterol. 2018 Oct 17;: Authors: Kane S Abstract Infliximab was the first FDA approved biologic for the treatment of Crohn’s disease. Data for its use before and during pregnancy in both females and males have been increasing over the last decade, but most studies have had fewer than 100 patients and inconsistent comparison to healthy control outcomes. New data from the TREAT Safety Registry have a robust N of female and male patients exposed to infliximab…

Read More

Safety and Tolerability of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease.

Related Articles Safety and Tolerability of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease. Am J Gastroenterol. 2018 Oct 17;: Authors: Ma D, Wong W, Aviado J, Rodriguez C, Wu H Abstract INTRODUCTION: Infliximab for inflammatory bowel disease (IBD) is FDA-approved to be administered 2 h or more. We adopted a new protocol to infuse infliximab over 1 h and in this study, we aimed to determine the safety of a 1-h infusion. METHODS: This retrospective cohort included adult IBD patients who received infliximab between June and December 2017 and compared…

Read More

Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience.

Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience. Inflamm Bowel Dis. 2018 Oct 16;: Authors: Pouillon L, Baumann C, Rousseau H, Choukour M, Andrianjafy C, Danese S, Peyrin-Biroulet L Abstract Background: Infliximab and adalimumab are widely used in the treatment of patients with ulcerative colitis (UC). There are few published data on the treatment persistence of infliximab and adalimumab in patients with UC. Methods: We aimed to compare the treatment persistence rates of infliximab versus adalimumab as first- and second-line tumor necrosis factor antagonists (anti-TNF),…

Read More

Letter: is there a role for infliximab biosimilar in patients with inflammatory bowel disease with secondary loss of response to infliximab innovator?

Related Articles Letter: is there a role for infliximab biosimilar in patients with inflammatory bowel disease with secondary loss of response to infliximab innovator? Aliment Pharmacol Ther. 2018 Nov;48(9):1037-1038 Authors: Orfanoudaki E, Drygiannakis I, Koutroubakis IE PMID: 30318690 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30318690?dopt=Abstract

Read More

Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting.

Related Articles Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting. Dig Dis Sci. 2018 Oct 11;: Authors: Checkley LA, Kristofek L, Kile S, Bolgar W Abstract BACKGROUND: Infliximab is a chimeric anti-tumor necrosis factor alpha (TNF-α) monoclonal antibody that ameliorates inflammation when it binds to and neutralizes TNF-α. It is often used in patients with Crohn’s disease and ulcerative colitis to reduce the severity of disease symptoms and induce disease remission. Infusions are generally administered in the hospital setting due to concerns over patient safety,…

Read More

Rare cause of rectal stenosis in a patient with long-term use of Infliximab and Mercaptopurine for ulcerative colitis.

Related Articles Rare cause of rectal stenosis in a patient with long-term use of Infliximab and Mercaptopurine for ulcerative colitis. Gut. 2018 Oct 09;: Authors: Hammoudi N, Gardair C, Tran-Minh ML, Allez M, Gornet JM Abstract QUESTION: A 58-year-old, non-smoker male patient with no family history was followed up since 2002 for ulcerative colitis (UC) located in the rectosigmoid. He was initially treated by salicylates alone until November 2008. Mercaptopurine was started in August 2009 for steroid dependence with primary failure despite adequate 6 thioguanine nucleotides (6 TGN) level. He…

Read More

A propensity score-matched comparison of infliximab and adalimumab in TNF-α inhibitors naïve and non-naïve patients with Crohn’s disease: real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD).

A propensity score-matched comparison of infliximab and adalimumab in TNF-α inhibitors naïve and non-naïve patients with Crohn’s disease: real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD). J Crohns Colitis. 2018 Oct 06;: Authors: Macaluso FS, Fries W, Privitera AC, Cappello M, Siringo S, Inserra G, Magnano A, Di Mitri R, Mocciaro F, Belluardo N, Scarpulla G, Magrì G, Trovatello A, Carroccio A, Genova S, Bertolami C, Vassallo R, Romano C, Citrano M, Accomando S, Ventimiglia M, Renna S, Orlando R, Rizzuto G, Porcari S, Ferracane C, Cottone…

Read More

Combination Therapy with Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy-a Post-hoc analysis.

Combination Therapy with Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy-a Post-hoc analysis. Clin Gastroenterol Hepatol. 2018 Sep 26;: Authors: Colombel JF, Adedokun OJ, Gasink C, Gao LL, Cornillie FJ, D’Haens GR, Rutgeerts PJ, Reinisch W, Sandborn WJ, Hanauer SB Abstract BACKGROUND & AIMS: Among immunosuppressive- and biologic-naïve patients with moderate to severely active Crohn’s disease (CD), a higher proportion of those treated with the combination of infliximab and azathioprine achieved corticosteroid-free remission at week 26 (CSFR26) than those given infliximab monotherapy; patients given the combination therapy also had…

Read More

Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease.

Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease. J Crohns Colitis. 2018 Sep 19;: Authors: van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, Vermeire S Abstract Background: The role of therapeutic drug monitoring for infliximab [IFX] therapy in children with inflammatory bowel disease [IBD] is poorly investigated. We determined if IFX exposure correlates with long-term remission in children. Methods: In this retrospective study, all children with Crohn’s disease [CD] and ulcerative colitis [UC], receiving maintenance IFX…

Read More
<< Go Back